Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.41 |
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | ESRRB | O95718 | 1/20 | 0.38 |
| ▸ | ESRRG | P62508 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6396317 | 0.84 | ALDH1A1 (0.55) | THRBKDM4EALDH1A1POLBGAA | |
| SCHEMBL9969427 | 0.84 | KMT2A (0.57) | S1PR1HSD17B10 | |
| SCHEMBL18701020 | 0.82 | MLYCD (0.42) | THRBTHRASLC13A5S1PR1PLK1 | |
| SCHEMBL18531120 | 0.80 | CYP4F2 (0.44) | — | |
| SCHEMBL13139803 | 0.79 | MMP12 (0.53) | HSD17B10 | |
| SCHEMBL19002551 | 0.79 | CYP4A11 (0.62) | KDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL22040686 | 0.79 | HDAC1 (0.61) | — | |
| SCHEMBL5065524 | 0.79 | GSK3B (0.53) | THRBTHRA | |
| SCHEMBL20906861 | 0.79 | THRA (0.61) | THRBTHRAPLK1ALDH1A1ESRRG | |
| SCHEMBL15100965 | 0.77 | PLK1 (0.62) | THRBTHRAPLK1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11173157-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | Apros Therapeutics, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210000826-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS AS TLR7 MODULATORS | Apros Therapeutics, Inc. | 2021-01-07 | — | — | US | disclosed |
| US-10786502-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | Apros Therapeutics, Inc. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20190314372-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | Apros Therapeutics, Inc. | 2019-10-17 | — | — | US | disclosed |
| US-20180155298-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | Apros Therapeutics, Inc. | 2018-06-07 | — | — | US | disclosed |
| US-9804168-B2 | Biomarker discovery in complex biological fluid using bead or particle based libraries and diagnostic kits and therapeutics | OPKO PHARMACEUTICALS, LLC (US) | 2017-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000826-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS AS TLR7 MODULATORS | TLR7, TLR9, STING1 | THRB 3404/4885THRA 3566/4885SLC13A5 3786/4885 |
| US-20180155298-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | MAVS, TLR7, STING1 | THRB 3320/4885THRA 3611/4885SLC13A5 3531/4885 |
| US-20190314372-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | MAVS, TLR7, STING1 | THRB 3320/4885THRA 3611/4885SLC13A5 3531/4885 |
| US-11173157-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | TLR7, TLR9, MAVS | THRB 3059/4885THRA 3626/4885SLC13A5 4120/4885 |
| US-10786502-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | TLR7, TLR9, MAVS | THRB 3059/4885THRA 3626/4885SLC13A5 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.